Related Experiment Video

Updated: Aug 19, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Provocative results suggest lower BP targets may be advisable for CAD patients

    Disease Management Advisor
    |January 28, 2005
    PubMed

    Insights

    For patients with coronary artery disease (CAD), the choice of antihypertensive drug significantly impacts reduced morbidity and mortality. Physicians should carefully consider drug selection for better blood pressure (BP) management.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Established coronary artery disease (CAD) necessitates careful management of blood pressure (BP).
    • The selection of antihypertensive medications may influence patient outcomes beyond BP control.

    Purpose of the Study:

    • To investigate the impact of antihypertensive drug choice on morbidity and mortality in patients with established CAD.
    • To assess whether specific antihypertensive agents offer differential benefits in CAD management.

    Main Methods:

    • Analysis of results from the CAMELOT trial.
    • Evaluation of morbidity and mortality data based on antihypertensive drug usage.

    Main Results:

    • The choice of antihypertensive drug demonstrated a significant effect on reducing morbidity and mortality in patients with CAD.
    • Specific drug choices may be linked to differential patient benefits.

    Conclusions:

    • Antihypertensive drug selection is a critical factor for improving outcomes in CAD patients.
    • Further research is warranted to optimize antihypertensive therapy in this population.
    • There is potential for improved BP management even within current therapeutic targets.

    Related Concept Videos

    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Special considerations while measuring blood pressure01:28

    Special considerations while measuring blood pressure

    When assessing blood pressure (BP), healthcare professionals must consider various factors and potential unexpected outcomes to ensure accurate readings and provide proper patient care. Adhering to these guidelines is essential to achieving the most reliable results.
    Monitoring Both Arms:
    Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.